• Saburo Hamanaka, Chairman and Chief Executive Officer
• Mark Iwicki, President and Chief Operating Officer
  
• Nobuhiko Tamura, Executive Vice President and Chief Scientific Officer, Research and Development

Saburo Hamanaka
Chairman and Chief Executive Officer

Mr. Hamanaka joined Sepracor as a Member of the Board in October 2009 following the acquisition of the company by Dainippon Sumitomo Pharma Co., Ltd. (DSP). In February 2010, Mr. Hamanaka was appointed Chairman of Sepracor and in April 2010 was appointed Chairman and Chief Executive Officer.  Mr. Hamanaka has been a part of the DSP organization since July 2006 and also serves as Executive Officer of DSP.

Prior to joining DSP, Mr. Hamanaka was Corporate Officer and General Manager of U.S. Operations for Takeda Pharmaceuticals.  From 1998 to 2002, Mr. Hamanaka was President of Takeda Pharmaceutical North America based in Chicago and served in various roles at TAP Pharmaceuticals from 1983 to 1990.  Mr. Hamanaka began his career in the pharmaceutical industry in 1967 when he joined Takeda’s pharmaceutical operations in Japan.

Mark Iwicki
President and Chief Operating Officer

Mark Iwicki joined Sepracor in October 2007 as Executive Vice President and Chief Commercial Officer, and in February 2010, was promoted to President and Chief Operating Officer and became a member of Sepracor's Board of Directors. Mr. Iwicki is responsible for leading Sepracor's Commercial Group, Supply Chain Operations, Human Resources & Administration, Information Technology and Corporate Development & Licensing.

Prior to joining Sepracor, Mr. Iwicki held senior positions at Novartis Pharmaceuticals from 1998 through 2007, most recently as Vice President and Cardiovascular Business Franchise Head. Prior to that, Mr. Iwicki was head of the Arthritis, Bone, Gastrointestinal, HRT, Infectious Disease and Urology Business Franchise Head. Before joining Novartis, Mr. Iwicki held various sales and marketing positions at Merck and Astra Merck. Mr. Iwicki earned his B.S. from Ball State University and an MBA from Loyola College.

Nobuhiko Tamura
Executive Vice President and Chief Scientific Officer, Research and Development

Mr. Nobuhiko Tamura is currently the Executive Vice President and Chief Scientific Officer for Research and Development at Sepracor Inc. He assumed this position in January 2010. He held the position of President of Dainippon Sumitomo Pharma America (DSPA) from 2007 until March 2010, and he is an Executive Officer of Dainippon Sumitomo Pharma Co., Ltd. (DSP).

Mr. Tamura began his career at Sumitomo Chemical Co., Ltd. as a researcher in the Pharmaceutical Division engaged in new drug discoveries. In 1984, he was transferred to Sumitomo Pharmaceutical Co., Ltd. (SP) upon its establishment as a subsidiary of Sumitomo Chemical. After six years in the discovery laboratory of SP, he broadened his experience working in a business development group in New York and served as a U.S. representative of SP America for five years. From 1994 to 2007, Mr. Tamura transitioned to the R&D Division of SP and DSP, leading several biological projects and new chemical entities for the treatment of central nervous system and other diseases. During this time, he also cultivated alliances with universities.